de Vries Marjolein P, van den Bemt Lisette, Thoonen Bart P A, Muris Jean W M, van Schayck C P Onno
Department of General Practice, Research Institute Caphri, Maastricht University, P.O. Box 616, 6200 MD Maastricht, The Netherlands.
Prim Care Respir J. 2006 Apr;15(2):110-5. doi: 10.1016/j.pcrj.2006.01.001. Epub 2006 Feb 20.
To assess whether exposure to house dust mite (HDM) allergens hampers a tapering off of inhaled corticosteroid (ICS) dosage in HDM-sensitive asthma patients.
Asthma patients sensitised to HDM allergens and using ICS were selected from general practices for this observational study. Dust samples from bed mattresses were taken to assess exposure ('no', 'low', 'intermediate' or 'high') to HDM allergens with a semi-quantitative test (Acarex). Patients were trained to use a self management plan to adjust the dose of ICS according to symptoms and peak flow. The observation period was three months.
Outcomes from 123 patients were analysed. Within the 'no' and 'low' HDM exposure groups the proportion of patients who increased the dosage of their ICS medication was significantly lower than the proportion who tapered off or remained on the same dose of ICS. The group with high exposure to HDM allergens had the highest proportion of patients who increased their dose of ICS (p = 0.055).
High exposure to HDM allergens seems to coincide with the use of higher dose ICS treatment in asthma patients sensitised to HDM allergens.
评估暴露于屋尘螨(HDM)过敏原是否会阻碍HDM敏感型哮喘患者减少吸入性糖皮质激素(ICS)的剂量。
从普通诊所选取对HDM过敏原敏感且正在使用ICS的哮喘患者进行这项观察性研究。采集床垫的灰尘样本,通过半定量检测(Acarex)评估对HDM过敏原的暴露情况(“无”、“低”、“中”或“高”)。对患者进行培训,使其使用自我管理计划根据症状和呼气峰流速来调整ICS剂量。观察期为三个月。
分析了123例患者的结果。在“无”和“低”HDM暴露组中,增加ICS药物剂量的患者比例显著低于减少剂量或维持相同ICS剂量的患者比例。HDM过敏原高暴露组中增加ICS剂量的患者比例最高(p = 0.055)。
对于对HDM过敏原敏感的哮喘患者,高暴露于HDM过敏原似乎与使用更高剂量的ICS治疗同时出现。